193 related articles for article (PubMed ID: 32828790)
1. Posaconazole and fluconazole prophylaxis during induction therapy for pediatric acute lymphoblastic leukemia.
Zhang T; Bai J; Huang M; Li R; Liu Y; Liu A; Liu J
J Microbiol Immunol Infect; 2021 Dec; 54(6):1139-1146. PubMed ID: 32828790
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole versus voriconazole as antifungal prophylaxis during induction therapy for acute myelogenous leukemia or myelodysplastic syndrome.
Phillips K; Cirrone F; Ahuja T; Siegfried J; Papadopoulos J
J Oncol Pharm Pract; 2019 Mar; 25(2):398-403. PubMed ID: 30319061
[TBL] [Abstract][Full Text] [Related]
3. Cost-benefit Analysis of Posaconazole Versus Fluconazole or Itraconazole as a Primary Antifungal Prophylaxis in High-risk Hematologic Patients: A Propensity Score-matched Analysis.
Cho SY; Lee DG; Choi JK; Lee HJ; Kim SH; Park SH; Choi SM; Choi JH; Yoo JH; Kim YJ; Kim HJ; Min WS; Back H; Kang S; Lee EK
Clin Ther; 2015 Sep; 37(9):2019-27. PubMed ID: 26188835
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole prophylaxis in leukemic patients: A retrospective single-center study.
Bui V; Walker SA; Elligsen M; Vyas A; Kiss A; Palmay L
J Oncol Pharm Pract; 2020 Jun; 26(4):873-881. PubMed ID: 31566111
[TBL] [Abstract][Full Text] [Related]
5. Decreased invasive fungal disease but no impact on overall survival by posaconazole compared to fluconazole prophylaxis: a retrospective cohort study in patients receiving induction therapy for acute myeloid leukaemia/myelodysplastic syndromes.
Dahlén T; Kalin M; Cederlund K; Nordlander A; Björkholm M; Ljungman P; Blennow O
Eur J Haematol; 2016 Feb; 96(2):175-80. PubMed ID: 25880378
[TBL] [Abstract][Full Text] [Related]
6. [Efficacy of Posaconazole for Primary Prophylaxis in the Induction Therapy of Childhood Acute Lymphoblastic Leukemia].
Zhang YT; Wang J; Zhou DH; Fang JP
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1710-1713. PubMed ID: 34893098
[TBL] [Abstract][Full Text] [Related]
7. Comparison of invasive fungal diseases between patients with acute myeloid leukemia receiving posaconazole prophylaxis and those not receiving prophylaxis: A single-center, observational, case-control study in South Korea.
Yang E; Choi EJ; Park HS; Lee SO; Choi SH; Kim YS; Lee JH; Lee JH; Lee KH; Kim SH
Medicine (Baltimore); 2021 May; 100(20):e25448. PubMed ID: 34011022
[TBL] [Abstract][Full Text] [Related]
8. [Breakthrough of invasive fungal disease with posaconazole as primary prophylaxis after induction chemotherapy for acute myeloid leukemia].
Pei RZ; Lu Y; Zhang PS; Liu XH; Chen D; Du XH; Sha KY; Li SY; Cao JJ; Chen LG; Zhuang XX; Tang SH
Zhonghua Nei Ke Za Zhi; 2020 Mar; 59(3):213-217. PubMed ID: 32146748
[No Abstract] [Full Text] [Related]
9. Long-Lasting Protective Effect of Posaconazole Prophylaxis in Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Stem Cell Transplantation.
Busca A; Candoni A; Audisio E; Passera R; Bruno B; Monaco F; Mordini N; Vacca A; Delia M; Aversa F; Pagano L
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2214-2219. PubMed ID: 27667012
[TBL] [Abstract][Full Text] [Related]
10. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia.
Cornely OA; Maertens J; Winston DJ; Perfect J; Ullmann AJ; Walsh TJ; Helfgott D; Holowiecki J; Stockelberg D; Goh YT; Petrini M; Hardalo C; Suresh R; Angulo-Gonzalez D
N Engl J Med; 2007 Jan; 356(4):348-59. PubMed ID: 17251531
[TBL] [Abstract][Full Text] [Related]
11. Clinical efficacy and safety of primary antifungal prophylaxis with posaconazole versus fluconazole in allogeneic blood hematopoietic stem cell transplantation recipients-A retrospective analysis of a single medical center in Taiwan.
Wang CH; Kan LP; Lin HA; Chang FY; Wang NC; Lin TY; Chao TY; Kao WY; Ho CL; Chen YC; Dai MS; Chang PY; Wu YY; Lin JC
J Microbiol Immunol Infect; 2016 Aug; 49(4):531-8. PubMed ID: 25440977
[TBL] [Abstract][Full Text] [Related]
12. Impact of patient education on plasma concentrations and effectiveness of posaconazole oral suspension under clinical conditions.
Geist MJP; Egerer G; Mikus G; Blank A; Hohmann N; Heinz WJ; Carls A
Basic Clin Pharmacol Toxicol; 2019 Jan; 124(1):56-61. PubMed ID: 29989301
[TBL] [Abstract][Full Text] [Related]
13. Impact of fluconazole versus posaconazole prophylaxis on the incidence of fungal infections in patients receiving induction chemotherapy for acute myeloid leukemia.
Devanlay C; Tavernier-Tardy E; Bourmaud A; Falk AT; Raberin H; Menguy S; Guyotat D; Magné N; Cornillon J
Biomed J; 2015; 38(3):235-43. PubMed ID: 25355388
[TBL] [Abstract][Full Text] [Related]
14. Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy.
Park H; Youk J; Shin DY; Hong J; Kim I; Kim NJ; Lee JO; Bang SM; Yoon SS; Park WB; Koh Y
BMC Cancer; 2019 Apr; 19(1):358. PubMed ID: 30991992
[TBL] [Abstract][Full Text] [Related]
15. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period.
Ananda-Rajah MR; Grigg A; Downey MT; Bajel A; Spelman T; Cheng A; Thursky KT; Vincent J; Slavin MA
Haematologica; 2012 Mar; 97(3):459-63. PubMed ID: 22058198
[TBL] [Abstract][Full Text] [Related]
16. SEIFEM 2010-E: economic evaluation of posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia receiving induction chemotherapy.
Busca A; Lessi F; Verga L; Candoni A; Cattaneo C; Cesaro S; Dragonetti G; Delia M; De Luca A; Guglielmi G; Tumbarello M; Martino G; Nadali G; Fanci R; Picardi M; Potenza L; Nosari A; Aversa F; Pagano L;
Leuk Lymphoma; 2017 Dec; 58(12):2859-2864. PubMed ID: 28508692
[TBL] [Abstract][Full Text] [Related]
17. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease.
Ullmann AJ; Lipton JH; Vesole DH; Chandrasekar P; Langston A; Tarantolo SR; Greinix H; Morais de Azevedo W; Reddy V; Boparai N; Pedicone L; Patino H; Durrant S
N Engl J Med; 2007 Jan; 356(4):335-47. PubMed ID: 17251530
[TBL] [Abstract][Full Text] [Related]
18. Itraconazole vs. posaconazole for antifungal prophylaxis in patients with acute myeloid leukemia undergoing intensive chemotherapy: A retrospective study.
Copley MS; Waldron M; Athans V; Welch SC; Brizendine KD; Cober E; Siebenaller C
Int J Antimicrob Agents; 2020 Mar; 55(3):105886. PubMed ID: 31926286
[TBL] [Abstract][Full Text] [Related]
19. Management of Invasive Fungal Infections in Pediatric Acute Leukemia and the Appropriate Time for Restarting Chemotherapy.
Tüfekçi Ö; Yılmaz Bengoa Ş; Demir Yenigürbüz F; Şimşek E; Karapınar TH; İrken G; Ören H
Turk J Haematol; 2015 Dec; 32(4):329-37. PubMed ID: 25913290
[TBL] [Abstract][Full Text] [Related]
20. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).
Mellinghoff SC; Panse J; Alakel N; Behre G; Buchheidt D; Christopeit M; Hasenkamp J; Kiehl M; Koldehoff M; Krause SW; Lehners N; von Lilienfeld-Toal M; Löhnert AY; Maschmeyer G; Teschner D; Ullmann AJ; Penack O; Ruhnke M; Mayer K; Ostermann H; Wolf HH; Cornely OA
Ann Hematol; 2018 Feb; 97(2):197-207. PubMed ID: 29218389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
